Commentary

Video

PRO Data for Mirvetuximab Soravtansine From MIRASOL in FRa+ Platinum-Resistant Ovarian Cancer

Author(s):

Bhavana Pothuri, MD,Tiffany Redfern, MD, FACOG

Fact checked by:

Chris Ryan

Bhavana Pothuri, MD, and Tiffany Redfern, MD, FACOG, on patient-reported outcome data for mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity
View More
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity
View More
Related Content
Solid tumors | Image Credit: © Kellie Ehrmann/MJH Life Sciences Using AI
May 15th 2025

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

Diane M. Simeone, MD; Marwan G. Fakih, MD
December 18th 2023

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

Bradley Monk, MD, FACOG, FACS, gynecologic oncologist, medical director, Late-Stage Clinical Research Program, Florida Cancer Specialists & Research Institute
May 12th 2025

Avutometinib/Defactinib Expands Treatment Options for KRAS-Mutant Low-Grade Serous Ovarian Cancer

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

The OncFive: Top Oncology Articles for the Week of 5/4
May 10th 2025

The OncFive: Top Oncology Articles for the Week of 5/4

The FDA has granted accelerated approval to avutometinib plus defactinib (Avmapki Fakzynja) for select KRAS-mutated recurrent low-grade serous ovarian cancer.
May 8th 2025

FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer